When is a Target Not a Target?
Executive Summary
Medarex is reevaluating its plans to bring 10 antibodies into the clinic each year, in part because targets identified by its array of young partners are taking a lot of work to validate. The company has gained appreciation for vaccines and for the potential of using antibodies as general immune stimulants rather than specifically targeted therapeutics.